Treatment for Mycosis Fungoides using Hypericin Ointment and Light

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of synthetic hypericin ointment (HyBryte) combined with visible light therapy in treating patients with mycosis fungoides, a type of cutaneous T-cell lymphoma. Participants will apply the ointment twice a week, followed by light activation 24 hours later. The trial will last up to 54 weeks, during which the severity of lesions will be monitored using specific scoring systems. The study is designed to assess the therapeutic response and safety of this treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosis fungoides), Stage 1A, Stage 1B, or Stage 2A.

(Stage 1 is divided into stages 1A and 1B as follows: Stage 1A: Patches, papules, and/or plaques cover less than 10% of the skin surface. Stage 1B: Patches, papules, and/or plaques cover 10% or more of the skin surface. Stage 2A: Patches, papules, and/or plaques cover any amount of skin surface. Lymph nodes are abnormal, but they are not cancerous.)

* Subjects willing to follow the clinical protocol and voluntarily give their written informed consent
* Female subjects not pregnant nor nursing and willing to undergo a pregnancy test within 21 days prior to treatment initiation and agree to use a medically accepted method of birth control such as oral contraceptives (birth control pill), Barrier method (condom plus spermicide or diaphragm plus spermicide) or abstaining from intercourse while on study

Exclusion Criteria:

* History of allergy or hypersensitivity to any of the components of SGX301
* Pregnancy or mothers who are breast-feeding
* Males and females not willing to use effective contraception
* Subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g., porphyria, systemic lupus erythematosus, Sjogren's, etc.).
* Subjects whose condition is spontaneously improving.
* Subjects receiving topical steroids or other topical treatments (e.g., nitrogen mustard) on lesions for CTCL within 2 weeks of enrollment
* Subjects receiving systemic steroids, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment
* Subjects who have received electron beam irradiation within 3 months of enrollment
* Subjects with a history of significant systemic immunosuppression
* Subjects taking other investigational drugs or drugs of abuse within 30 days of enrollment
* Subject with any condition that, in the judgment of the PI, is likely to interfere with participation in the study
* Subjects receiving drugs known to cause photosensitization within 2 weeks of starting SGX301 therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks.

Where it's running

• Perelman Center for Advanced Medicine
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Laura Cesar
• Email: laura.cesar@pennmedicine.upenn.edu
• Phone: 4458006538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Using photopheresis to treat early-stage Mycosis Fungoides

  This study is testing if a light-based treatment called photopheresis can help people with early-stage Mycosis Fungoides, a type of skin lymphoma, feel better.

  Recruiting Phase 2 Columbia University · New York, New York · NCT05680558

• Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma

  This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting at 10 sites Phase 1 SciTech Development, Inc. · Scottsdale, Arizona and 9 other locations · NCT04234048

• Collection of blood, urine, and tissue samples for research on skin conditions

  This study is collecting blood, urine, and tissue samples from people with skin conditions like cutaneous T-cell lymphoma, eczema, and atopic dermatitis to help improve treatments in the future.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT00177268

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.